5th Annual Cedars-Sinai Gastrointestinal Tumor Conference 2024

Saturday, March 23, 2024, 7:30 AM – 12:30 PM PST, Cedars-Sinai Harvey Morse Conference Center, Los Angeles, CA

Target Audience

Overview

The 5th Annual Cedars-Sinai Gastrointestinal Tumor Conference will provide concise and comprehensive updates on the most recent research and advances in therapy for gastrointestinal cancers. A stellar faculty has been assembled to share developments in precision medicine, research, and immunotherapeutic approaches to the treatment of cancers of the pancreas, liver, and gastric/esophagus.

Invited faculty will present a comprehensive bench to bedside review of immune therapy for GI malignancies, detail immune therapies for pancreatic cancer, and explore advances in biomarkers and immunotherapy in gastroesophageal cancers. Biomarker strategies for neuroendocrine and rare tumors will be presented and participants will also have an opportunity to review immune-related toxicities. Join your colleagues for this important half day educational activity that will enhance your understanding of GI cancers and provide you with valuable information to inform your clinical decision-making and treatment approaches for your patients.

Objectives

1. Consider advances in biomarkers and therapy to better inform treatment decision-making for patients with gastroesophageal cancers
2. Use AJCC or other appropriate staging in clinical practice, including the use of appropriate prognostic indicators and evidence-based national guidelines for treatment planning
3. Evaluate the basic science of immune therapy for GI malignancies and the implications for transfer from bench to bedside
4. Increase knowledge of therapy for neuroendocrine tumors and biomarker identification of novel therapies
5. Identify and implement optimal strategies for managing therapy-related side effects and toxicities in patients treated with therapeutic agents
6. Anticipate the needs, problems, and issues of cancer survivors and develop an individualized wellness plan in partnership with cancer survivors, their families and the healthcare team